Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in patients with glaucoma or ocular hypertension.
The presentation highlighted that the 420-patient study, which started in August 2018, was progressing well, having reached 90% enrollment. The presentation also highlighted the potential for NCX 470 to become the best-in-class first line therapy for lowering IOP in patients with glaucoma or ocular hypertension.
NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently in a multicenter, US phase 2 clinical study for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Topline data is expected in Q4 of this year
The presentation was entitled “Site Initiation Rates and Subject Enrollment Rates for 28-Day, First-in-Human Phase 2 Clinical Study of NCX 470: Novel NO-Donating Bimatoprost Analog.”